The use of HEPES-buffer in the production of gallium-68 radiopharmaceuticals – time to reconsider strict pharmacopoeial limits?
Date
2021-04-01
Journal Title
Journal ISSN
Volume Title
Publisher
SpringerOpen (part of Springer Nature)
Abstract
ENGLISH ABSTRACT: HEPES (4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid) is a buffer that is used in
the radiolabelling of gallium-68 compounds. The beneficial effects of HEPES on
molar activity in bioconjugates have been well described. Current strict regulations
on the HEPES content in radiopharmaceuticals limit its use when intended for
parenteral administration.
This short communication summarizes data from the literature on the toxicity of
HEPES in dogs after intravenous infusion and the subsequent use in humans. We
also highlight the use of HEPES in an FDA labelled intravenous drug formulation.
Regulatory institutions may consider this data to review current strict limits.
Description
CITATION: Le Roux, J., Kleynhans, J. & Rubow, S. 2021. The use of HEPES-buffer in the production of gallium-68 radiopharmaceuticals – time to reconsider strict pharmacopoeial limits?. EJNMMI Radiopharmacy and Chemistry, 6:15, doi:10.1186/s41181-021-00129-w.
The original publication is available at https://ejnmmipharmchem.springeropen.com
The original publication is available at https://ejnmmipharmchem.springeropen.com
Keywords
HEPES, Radiopharmaceuticals, Gallium, Pharmacopoeias
Citation
Le Roux, J., Kleynhans, J. & Rubow, S. 2021. The use of HEPES-buffer in the production of gallium-68 radiopharmaceuticals – time to reconsider strict pharmacopoeial limits?. EJNMMI Radiopharmacy and Chemistry, 6:15, doi:10.1186/s41181-021-00129-w